{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T07:35:09Z","timestamp":1783496109394,"version":"3.55.0"},"reference-count":97,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.semnephrol.2023.151476","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T21:16:44Z","timestamp":1706131004000},"page":"151476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["How to Ensure Patency of the Extracorporeal Circuit in Hemodialysis: Global Perspectives"],"prefix":"10.1016","volume":"43","author":[{"given":"Alba","family":"Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almudena","family":"Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Davenport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.semnephrol.2023.151476_bib0001","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/sdi.13070","article-title":"The rationale and clinical potential of on-line hemodiafiltration as renal replacement therapy","volume":"35","author":"Canaud","year":"2022","journal-title":"Semin Dial."},{"key":"10.1016\/j.semnephrol.2023.151476_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.semnephrol.2023.151473","article-title":"Clotting of the extracorporeal circuit in hemodialysis\u2014beyond contact activated coagulation","author":"Engelen","year":"2023","journal-title":"Semin Nephrol."},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151476_bib0003","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrneph.2011.88","article-title":"What are the anticoagulation options for intermittent hemodialysis?","volume":"7","author":"Davenport","year":"2011","journal-title":"Nat Rev Nephrol"},{"issue":"7328","key":"10.1016\/j.semnephrol.2023.151476_bib0004","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(64)92409-2","article-title":"Heparin infusion of artery and vein for repeated haemodialysis in acute renal failure","volume":"1","author":"Cash","year":"1964","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151476_bib0005","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/sdi.12932","article-title":"Anticoagulation in hemodialysis: A narrative review","volume":"34","author":"Claudel","year":"2021","journal-title":"Semin Dial"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151476_bib0006","first-page":"641","article-title":"Single-bolus tinzaparin anticoagulation in extended hemodialysis session: A feasibility study","volume":"4","author":"Harvey","year":"2023","journal-title":"Kidney360"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151476_bib0007","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40360-023-00643-4","article-title":"Novel fondaparinux protocol for anticoagulation therapy in adults with renal failure and suspected heparin-induced thrombocytopenia: A retrospective review of institutional protocol","volume":"24","author":"Ghaziri","year":"2023","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.semnephrol.2023.151476_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.semnephrol.2023.151474","article-title":"Detection and scoring of extracorporeal circuit clotting in hemodialysis","author":"Vanommeslaeghe","year":"2023","journal-title":"Semin Nephrol."},{"key":"10.1016\/j.semnephrol.2023.151476_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.semnephrol.2023.151477","article-title":"Laboratory monitoring of heparin anticoagulation in hemodialysis: Rationale and strategies","author":"Chiasakul","year":"2023","journal-title":"Semin Nephrol."},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151476_bib0010","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1440-1797.2010.01298.x","article-title":"Review: Anticoagulation for haemodialysis","volume":"15","author":"Suranyi","year":"2010","journal-title":"Nephrology (Carlton)"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151476_bib0011","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1365-2141.2008.07119.x","article-title":"The story of the discovery of heparin and warfarin","volume":"141","author":"Wardrop","year":"2008","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151476_bib0012","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1309\/LMSXWC3A4LBIJP2B","article-title":"Heparins: Clinical use and laboratory monitoring","volume":"41","author":"Hoffman","year":"2010","journal-title":"Lab Med."},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151476_bib0013","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1440-1797.2009.01135.x","article-title":"Review article: Low-molecular-weight heparin as an alternative anticoagulant to unfractionated heparin for routine outpatient haemodialysis treatments","volume":"14","author":"Davenport","year":"2009","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.semnephrol.2023.151476_bib0014","unstructured":"Herrero Calvo JA, S\u00e1nchez Gonz\u00e1lez C, Tornero Molina F. Anticoagulaci\u00f3n en hemodi\u00e1lisis. In: Lorenzo V, L\u00f3pez G\u00f3mez JM, eds. Nefrolog\u00eda al D\u00eda. Accessed September 8, 2020. https:\/\/www.nefrologiaaldia.org\/580"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151476_bib0015","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nbt1407","article-title":"Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events","volume":"26","author":"Guerrini","year":"2008","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.semnephrol.2023.151476_bib0016","doi-asserted-by":"crossref","DOI":"10.1177\/10760296211052293","article-title":"General considerations for diversifying heparin drug products by improving the current heparin manufacturing process and reintroducing bovine sourced heparin to the US market","volume":"27","author":"Al-Hakim","year":"2021","journal-title":"Clin Appl Thromb Hemost"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151476_bib0017","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1542-4758.2007.00166.x","article-title":"Essentials of anticoagulation in hemodialysis","volume":"11","author":"Fischer","year":"2007","journal-title":"Hemodial Int"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151476_bib0018","first-page":"171","article-title":"Anticoagulation options for intermittent haemodialysis","volume":"58","author":"Davenport","year":"2006","journal-title":"Minerva Urol Nefrol"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151476_bib0019","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/j.1875-9114.1990.tb02594.x","article-title":"Pharmacokinetics and pharmacodynamics of heparin during hemodialysis: Interpatient and intrapatient variability","volume":"10","author":"Kandrotas","year":"1990","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151476_bib0020","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1046\/j.1525-139X.2000.00052.x","article-title":"Anticoagulation for intermittent hemodialysis","volume":"13","author":"Ouseph","year":"2000","journal-title":"Semin Dial"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151476_bib0021","first-page":"303","article-title":"Heparin elimination and hemostasis in hemodialysis","volume":"22","author":"Wilhelmsson","year":"1984","journal-title":"Clin Nephrol"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151476_bib0022","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/pds.3595","article-title":"Correlates and variance decomposition analysis of heparin dosing for maintenance hemodialysis in older US patients","volume":"23","author":"Shen","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151476_bib0023","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/039139888400700508","article-title":"Heparin for hemodialysis: Practical guidelines for administration and monitoring","volume":"7","author":"Mingardi","year":"1984","journal-title":"Int J Artif Organs"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151476_bib0024","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1186\/s12882-019-1527-3","article-title":"Renal Association Clinical Practice Guideline on haemodialysis","volume":"20","author":"Ashby","year":"2019","journal-title":"BMC Nephrol"},{"issue":"suppl 2","key":"10.1016\/j.semnephrol.2023.151476_bib0025","first-page":"ii5","article-title":"EBPG guideline on dialysis strategies","volume":"22","author":"Tattersall","year":"2007","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151476_bib0028","first-page":"122","article-title":"Protamine-associated hypotension in patients on hemodialysis: Retrospective study and prevalence of antiprotamine antibodies","volume":"72","author":"Tsai","year":"2009","journal-title":"Clin Nephrol"},{"issue":"suppl 1","key":"10.1016\/j.semnephrol.2023.151476_bib0026","first-page":"S43","article-title":"Optimization of heparin anticoagulation for hemodialysis","volume":"15","author":"Davenport","year":"2011","journal-title":"Hemodial Int"},{"issue":"2 suppl","key":"10.1016\/j.semnephrol.2023.151476_bib0027","doi-asserted-by":"crossref","first-page":"e24S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Garcia","year":"2012","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151476_bib0029","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1525-1594.1979.tb03807.x","article-title":"Low-dose heparin in routine hemodialysis monitored by activated partial thromboplastin time","volume":"3","author":"Shapiro","year":"1979","journal-title":"Artif Organs"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151476_bib0030","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/hdi.12563","article-title":"Efficacy and safety of low-dose heparin in hemodialysis","volume":"22","author":"Murea","year":"2018","journal-title":"Hemodial Int"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151476_bib0031","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.2741\/4462","article-title":"Heparin and anticoagulation","volume":"21","author":"Onishi","year":"2016","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151476_bib0032","first-page":"95","article-title":"Pharmacological and clinical differences between low-molecular-weight heparins","volume":"35","author":"Merli","year":"2010","journal-title":"P T"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151476_bib0033","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/jth.13237","article-title":"Biosimilars of low-molecular-weight heparin products: Fostering competition or reducing \u201cbiodiversity\u201d?","volume":"14","author":"Harenberg","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"suppl 3","key":"10.1016\/j.semnephrol.2023.151476_bib0034","first-page":"5","article-title":"Production and chemical processing of low molecular weight heparins","volume":"25","author":"Linhardt","year":"1999","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151476_bib0035","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/0049-3848(91)90141-I","article-title":"Delayed elimination of enoxaparin in patients with chronic renal insufficiency","volume":"63","author":"Cadroy","year":"1991","journal-title":"Thromb Res"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151476_bib0036","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000046675","article-title":"Comparison between tinzaparin and standard heparin for chronic hemodialysis in a Canadian center","volume":"22","author":"Lord","year":"2002","journal-title":"Am J Nephrol"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151476_bib0037","first-page":"143","article-title":"Spanish study of anticoagulation in haemodialysis","volume":"32","author":"Herrero-Calvo","year":"2012","journal-title":"Nefrologia"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151476_bib0038","doi-asserted-by":"crossref","first-page":"335","DOI":"10.5414\/CPP43335","article-title":"Comparison of two low-molecular weight heparins (LMWHs), tinzaparin and bemiparin, during hemodialysis","volume":"43","author":"Christidou","year":"2005","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.semnephrol.2023.151476_bib0040","unstructured":"Ministerio de Sanidad, Pol\u00edtica Social e Igualdad. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios., Fragmin data sheet. Accessed February 2, 2023. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/61523\/FT_61523.html"},{"key":"10.1016\/j.semnephrol.2023.151476_bib0039","unstructured":"Ministerio de Sanidad, Pol\u00edtica Social e Igualdad. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios,Clexane data sheet. Accessed February 2, 2023. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/61523\/FT_61523.html"},{"key":"10.1016\/j.semnephrol.2023.151476_bib0043","unstructured":"Ministerio de Sanidad, Pol\u00edtica Social e Igualdad. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios., Fraxiparin data sheet. Accessed February 2, 2023. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/58983\/FT_58983.html"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151476_bib0041","doi-asserted-by":"crossref","first-page":"990","DOI":"10.3109\/0886022X.2011.618905","article-title":"Clinical safety and anticoagulation efficacy of low-molecular-weight heparins in chronic hemodialysis patients: A single medical center experience","volume":"33","author":"Chuang","year":"2011","journal-title":"Ren Fail"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151476_bib0042","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00044011-200323020-00002","article-title":"Randomised long-term comparison of tinzaparin and dalteparin in haemodialysis","volume":"23","author":"Beijering","year":"2003","journal-title":"Clin Drug Investig"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151476_bib0044","first-page":"322","article-title":"Comparison of different routes of administration of nadroparin in hemodialysis","volume":"52","author":"Vanuytsel","year":"1999","journal-title":"Clin Nephrol"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151476_bib0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128634","article-title":"Where and when to inject low molecular weight heparin in hemodiafiltration? A cross over randomised trial","volume":"10","author":"Dhondt","year":"2015","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151476_bib0046","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/nep.12681","article-title":"Arterial line versus venous line administration of low molecular weight heparin, enoxaparin for prevention of thrombosis in the extracorporeal blood circuit of patients on haemodialysis or haemodiafiltration: A randomized cross-over trial","volume":"21","author":"Kurtkoti","year":"2016","journal-title":"Nephrology (Carlton)"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151476_bib0047","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/MBC.0b013e32831bec0f","article-title":"Anticoagulation therapy during haemodialysis: A comparative study between two heparin regimens","volume":"20","author":"Sabry","year":"2009","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151476_bib0048","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1097\/01.ASN.0000145014.80714.35","article-title":"Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: A meta-analysis of randomized trials","volume":"15","author":"Lim","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151476_bib0049","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ekir.2020.11.020","article-title":"Arterial versus venous port site administration of nadroparin for preventing thrombosis of extracorporeal blood circuits in patients receiving hemodiafiltration treatment","volume":"6","author":"Hebibi","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151476_bib0050","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/hdi.13004","article-title":"Comparison of the injection of low-molecular weight heparin in the arterial vs. venous blood line for preventing extracorporeal circuit clotting during hemodialysis","volume":"26","author":"Belmouaz","year":"2022","journal-title":"Hemodial Int"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151476_bib0051","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/1744-9987.13652","article-title":"Expanded hemodialysis: Is anticoagulation of the dialysis circuit different from online hemodiafiltration and high-flux hemodialysis?","volume":"26","author":"Santos","year":"2022","journal-title":"Ther Apher Dial"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151476_bib0052","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/ckj\/sfaa057","article-title":"Efficacy of enoxaparin in preventing coagulation during high-flux haemodialysis, expanded haemodialysis and haemodiafiltration","volume":"14","author":"Santos","year":"2020","journal-title":"Clin Kidney J"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151476_bib0053","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1046\/j.1365-2141.2002.03233.x","article-title":"Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin","volume":"116","author":"Crowther","year":"2002","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151476_bib0054","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000502506","article-title":"Safety and efficacy of tinzaparin anticoagulation during nocturnal hemodialysis","volume":"50","author":"Bugeja","year":"2019","journal-title":"Am J Nephrol"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151476_bib0055","first-page":"270","article-title":"Anticoagulation with dalteparin and nadroparin in nocturnal haemodialysis","volume":"73","author":"Verhave","year":"2015","journal-title":"Neth J Med"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151476_bib0056","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/ckj\/sfw049","article-title":"Low-molecular weight heparin infusion as anticoagulation for haemodialysis","volume":"9","author":"Wong","year":"2016","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.semnephrol.2023.151476_bib0057","doi-asserted-by":"crossref","first-page":"e835","DOI":"10.7717\/peerj.835","article-title":"Efficacy and safety of low molecular weight heparin compared to unfractionated heparin for chronic outpatient hemodialysis in end stage renal disease: Systematic review and meta-analysis","volume":"3","author":"Shantha","year":"2015","journal-title":"PeerJ"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151476_bib0058","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12882-017-0596-4","article-title":"Safety of low-molecular-weight heparin compared to unfractionated heparin in hemodialysis: A systematic review and meta-analysis","volume":"18","author":"Lazrak","year":"2017","journal-title":"BMC Nephrol"},{"issue":"22","key":"10.1016\/j.semnephrol.2023.151476_bib0059","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1182\/bloodadvances.2018024489","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: Heparin-induced thrombocytopenia","volume":"2","author":"Cuker","year":"2018","journal-title":"Blood Adv"},{"issue":"15","key":"10.1016\/j.semnephrol.2023.151476_bib0060","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.2165\/00003495-200262150-00016","article-title":"Danaparoid: A review of its use in thromboembolic and coagulation disorders","volume":"62","author":"Ibbotson","year":"2002","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151476_bib0061","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/ajh.26194","article-title":"Comparative effectiveness and safety of anticoagulants for the treatment of heparin-induced thrombocytopenia","volume":"96","author":"Nilius","year":"2021","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151476_bib0062","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2165\/00003495-199754060-00008","article-title":"Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia","volume":"54","author":"Wilde","year":"1997","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151476_bib0063","doi-asserted-by":"crossref","first-page":"77","DOI":"10.5482\/HAMO-14-08-0036","article-title":"Anticoagulation in patients with impaired renal function and with haemodialysis. Anticoagulant effects, efficacy, safety, therapeutic options","volume":"35","author":"Harenberg","year":"2015","journal-title":"Hamostaseologie"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151476_bib0064","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1046\/j.1492-7535.2003.00022.x","article-title":"Anticoagulation options for pediatric hemodialysis","volume":"7","author":"Davenport","year":"2003","journal-title":"Hemodial Int"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151476_bib0065","doi-asserted-by":"crossref","first-page":"770","DOI":"10.5811\/westjem.2018.5.38235","article-title":"Emergency reversal of anticoagulation","volume":"20","author":"Yee","year":"2019","journal-title":"West J Emerg Med"},{"key":"10.1016\/j.semnephrol.2023.151476_bib0066","doi-asserted-by":"crossref","DOI":"10.1016\/j.semnephrol.2023.151479","article-title":"Immunologic effects of heparin associated with hemodialysis: Focus on heparin-induced thrombocytopenia","author":"Warkentin","year":"2023","journal-title":"Semin Nephrol."},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151476_bib0067","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s00134-009-1464-x","article-title":"Danaparoid cross-reactivity with heparin-induced thrombocytopenia antibodies: Report of 12 cases","volume":"35","author":"Tardy-Poncet","year":"2009","journal-title":"Intensive Care Med"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151476_bib0068","doi-asserted-by":"crossref","first-page":"76","DOI":"10.23736\/S0392-9590.19.04247-0","article-title":"Heparin-induced thrombocytopenia treated with fondaparinux: Single center experience","volume":"39","author":"Dulicek","year":"2020","journal-title":"Int Angiol"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151476_bib0069","first-page":"481","article-title":"Lepirudin in the management of patients with heparin-induced thrombocytopenia","volume":"2","author":"Petros","year":"2008","journal-title":"Biologics"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151476_bib0070","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.beha.2004.02.002","article-title":"Bivalent direct thrombin inhibitors: Hirudin and bivalirudin","volume":"17","author":"Warkentin","year":"2004","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151476_bib0071","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0009-9236(97)90151-X","article-title":"Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin","volume":"62","author":"Lef\u00e8vre","year":"1997","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151476_bib0072","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1067\/mcp.2002.124522","article-title":"Bivalirudin pharmacokinetics and pharmacodynamics: Effect of renal function, dose, and gender","volume":"71","author":"Robson","year":"2002","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151476_bib0073","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1160\/TH15-11-0847","article-title":"Argatroban pharmacokinetics and pharmacodynamics in critically ill cardiac surgical patients with suspected heparin-induced thrombocytopenia","volume":"115","author":"Keyl","year":"2016","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151476_bib0074","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2165\/00063030-199911060-00006","article-title":"Recombinant hirudin: Clinical pharmacology and potential applications in nephrology","volume":"11","author":"Vanholder","year":"1999","journal-title":"BioDrugs"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151476_bib0075","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2215\/CJN.02550706","article-title":"Hemofiltration of recombinant hirudin by different hemodialyzer membranes: Implications for clinical use","volume":"2","author":"Benz","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151476_bib0076","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1177\/0091270009350626","article-title":"Desirudin dosing and monitoring in moderate renal impairment","volume":"50","author":"Nafziger","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.semnephrol.2023.151476_bib0077","unstructured":"UW Medicine HIT Management Taskforce, Bivalirudin initial dosing | anticoagulation services 2013. Accessed February 7, 2023. https:\/\/sites.uw.edu\/anticoag\/conditions\/heparin-induced-thrombocytopenia-hit\/"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151476_bib0078","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1345\/aph.1Q177","article-title":"Bivalirudin dosing adjustments for reduced renal function with or without hemodialysis in the management of heparin-induced thrombocytopenia","volume":"45","author":"Tsu","year":"2011","journal-title":"Ann Pharmacother"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151476_bib0079","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1111\/j.1523-1755.2004.66022.x","article-title":"A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease","volume":"66","author":"Murray","year":"2004","journal-title":"Kidney Int"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151476_bib0080","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1007\/s00467-021-05020-z","article-title":"Anticoagulation in patients with acute kidney injury undergoing kidney replacement therapy","volume":"37","author":"Raina","year":"2022","journal-title":"Pediatr Nephrol"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151476_bib0081","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/nep.12096","article-title":"KHA-CARI guideline: Dialysis adequacy (haemodialysis): Dialysis membranes","volume":"18","author":"Kerr","year":"2013","journal-title":"Nephrology (Carlton)"},{"issue":"suppl 4","key":"10.1016\/j.semnephrol.2023.151476_bib0082","first-page":"S61","article-title":"The CARI guidelines. Dialysis adequacy (HD) guidelines","volume":"10","author":"Kerr","year":"2005","journal-title":"Nephrology (Carlton)"},{"issue":"suppl 1","key":"10.1016\/j.semnephrol.2023.151476_bib0083","doi-asserted-by":"crossref","first-page":"c241","DOI":"10.1159\/000328072","article-title":"Renal Association clinical practice guideline on haemodialysis","volume":"118","author":"Mactier","year":"2011","journal-title":"Nephron Clin Pract"},{"issue":"3 suppl 1","key":"10.1016\/j.semnephrol.2023.151476_bib0084","first-page":"S1","article-title":"Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology","volume":"17","author":"Jindal","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2023.151476_bib0086","doi-asserted-by":"crossref","unstructured":"European Best Practice Guidelines Expert Group on Hemodialysis; European Renal Association, Section V. Chronic intermittent haemodialysis and prevention of clotting in the extracorporal system, Nephrol Dial Transplant, 17 (suppl 7), 2002, 63\u201371.","DOI":"10.1093\/ndt\/17.suppl_7.63"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151476_bib0087","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1053\/j.ajkd.2015.07.015","article-title":"KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 update","volume":"66","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"suppl 1","key":"10.1016\/j.semnephrol.2023.151476_bib0088","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/1744-9987.12294","article-title":"Japanese Society for Dialysis Therapy clinical guideline for \u201cMaintenance hemodialysis: Hemodialysis prescriptions.\u201d","volume":"19","author":"Watanabe","year":"2015","journal-title":"Ther Apher Dial"},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151476_bib0089","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1093\/ndt\/14.11.2698","article-title":"Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation","volume":"14","author":"Saltissi","year":"1999","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151476_bib0090","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1542-4758.2011.00531.x","article-title":"Tinzaparin reduces health care resource use for anticoagulation in hemodialysis","volume":"15","author":"Pettigrew","year":"2011","journal-title":"Hemodial Int"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151476_bib0091","doi-asserted-by":"crossref","first-page":"c107","DOI":"10.1159\/000158561","article-title":"Comparison of tinzaparin and unfractionated heparin as anticoagulation on haemodialysis: Equal safety, efficacy and economical parity","volume":"110","author":"Bramham","year":"2008","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.semnephrol.2023.151476_bib0092","unstructured":"Accessed August 25, 2022. https:\/\/bnf.nice.org.uk\/drugs\/enoxaparin-sodium\/medicinal-forms\/"},{"key":"10.1016\/j.semnephrol.2023.151476_bib0093","unstructured":"Accessed August 25, 2022. https:\/\/www.sanidad.gob.es\/profesionales\/nomenclator.do?metodo=verDetalle&prod=719311"},{"key":"10.1016\/j.semnephrol.2023.151476_bib0094","unstructured":"Accessed August 25, 2022. https:\/\/bnfc.nice.org.uk\/drugs\/tinzaparin-sodium\/medicinal-forms\/"},{"key":"10.1016\/j.semnephrol.2023.151476_bib0095","unstructured":"Accessed August 25, 2022. https:\/\/www.sanidad.gob.es\/profesionales\/nomenclator.do?metodo=verDetalle&prod=697442"},{"key":"10.1016\/j.semnephrol.2023.151476_bib0096","unstructured":"Accessed August 25, 2022. https:\/\/bnf.nice.org.uk\/drugs\/fondaparinux-sodium\/medicinal-forms\/"},{"key":"10.1016\/j.semnephrol.2023.151476_bib0097","unstructured":"Accessed August 25, 2022. https:\/\/www.sanidad.gob.es\/profesionales\/nomenclator.do?metodo=verDetalle&prod=650591"},{"key":"10.1016\/j.semnephrol.2023.151476_bib0098","unstructured":"Accessed August 25, 2022. https:\/\/bnf.nice.org.uk\/drugs\/argatroban-monohydrate\/medicinal-forms\/"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929523001869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929523001869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T14:50:35Z","timestamp":1748357435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929523001869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":97,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0270929523001869"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151476","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How to Ensure Patency of the Extracorporeal Circuit in Hemodialysis: Global Perspectives","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151476","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"151476"}}